pT1 substaging in renal cell carcinoma: Validation of the 2002 TNM staging modification of malignant renal epithelial tumors

Mohamed Salama, K. Guru, H. Stricker, E. Peterson, J. Peabody, M. Menon, M. B. Amin, M. De Peralta-Venturina

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: Tumor size has been used as one of the criteria to stratify renal cell carcinoma (RCC) into different pathological stages (pT). The recent 2002 UICC/TNM classification of malignant epithelial renal tumors is modified to substratify pT1 RCC into pT1a (less than 4.0 cm) and pT1b (greater than 4.0 but less than 7.0 cm). In this study we ascertained if this stage modification has prognostic relevance. Materials and Methods: A total of 259 consecutive radical nephrectomy specimens of organ confined RCC from 1970 to 1997 at 1 institution, including 153 of conventional RCC (CRCC), 71 of papillary RCC, 28 of chromophobe RCC, 1 of collecting duct carcinoma and 6 of RCC not otherwise specified, with a mean clinical followup of 7.5 years (median 6.4) were included in the study. Results: There were 115 pT1a (44.4%), 95 pT1b (36.7%) and 49 pT2 tumors (18.9%). Disease recurrences (DR) and disease specific death occurred in 2 (1.7%) and 0 cases (0%) of pT1a, 7 (7.3%) and 5 (5.3%) of pT1b, and 16 (32.6%) and 12 (24.5%) of pT2. DR for pT1b was higher compared with pT1a (all histological subtypes RR 3.68), although this difference was not statistically significant (p = 0.106). If only CRCCs were analyzed, DR in the pT1b group was statistically higher compared with pT1a (RR 8.54, p = 0.047). Disease specific survival in pT1a could not be evaluated because no deaths occurred in this subgroup. DR and disease specific survival were significantly different between pT1b and pT2 tumors for all histological subtypes (RR 5.51, p = 0.001 and 5.49, p = 0.001) and for the CRCC subtype (RR 5.50, p = 0.001 and 5.18, p = 0.005, respectively). Using size as a continuous variable the logarithmic change in tumor size was a significant predictor of DR (RR 8.82, p = 0.001). All statistical analyses were adjusted for age and sex. Conclusions: Substaging RCC into pT1a and pT1b yields prognostically important information, validating the 2002 TNM modification for malignant renal epithelial malignancies. The substratification of pT1 is particularly useful in tumors with CRCC histology.

Original languageEnglish (US)
Pages (from-to)1492-1495
Number of pages4
JournalJournal of Urology
Volume173
Issue number5
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Neoplasm Staging
Renal Cell Carcinoma
Carcinoma
Kidney
Recurrence
Neoplasms
Nephrectomy
Histology

Keywords

  • Carcinoma
  • Kidney
  • Neoplasm staging
  • Renal cell

ASJC Scopus subject areas

  • Urology

Cite this

pT1 substaging in renal cell carcinoma : Validation of the 2002 TNM staging modification of malignant renal epithelial tumors. / Salama, Mohamed; Guru, K.; Stricker, H.; Peterson, E.; Peabody, J.; Menon, M.; Amin, M. B.; De Peralta-Venturina, M.

In: Journal of Urology, Vol. 173, No. 5, 01.01.2005, p. 1492-1495.

Research output: Contribution to journalArticle

Salama, M, Guru, K, Stricker, H, Peterson, E, Peabody, J, Menon, M, Amin, MB & De Peralta-Venturina, M 2005, 'pT1 substaging in renal cell carcinoma: Validation of the 2002 TNM staging modification of malignant renal epithelial tumors', Journal of Urology, vol. 173, no. 5, pp. 1492-1495. https://doi.org/10.1097/01.ju.0000154693.68717.12
Salama, Mohamed ; Guru, K. ; Stricker, H. ; Peterson, E. ; Peabody, J. ; Menon, M. ; Amin, M. B. ; De Peralta-Venturina, M. / pT1 substaging in renal cell carcinoma : Validation of the 2002 TNM staging modification of malignant renal epithelial tumors. In: Journal of Urology. 2005 ; Vol. 173, No. 5. pp. 1492-1495.
@article{5588843ccbda4a7aaf58a47593576031,
title = "pT1 substaging in renal cell carcinoma: Validation of the 2002 TNM staging modification of malignant renal epithelial tumors",
abstract = "Purpose: Tumor size has been used as one of the criteria to stratify renal cell carcinoma (RCC) into different pathological stages (pT). The recent 2002 UICC/TNM classification of malignant epithelial renal tumors is modified to substratify pT1 RCC into pT1a (less than 4.0 cm) and pT1b (greater than 4.0 but less than 7.0 cm). In this study we ascertained if this stage modification has prognostic relevance. Materials and Methods: A total of 259 consecutive radical nephrectomy specimens of organ confined RCC from 1970 to 1997 at 1 institution, including 153 of conventional RCC (CRCC), 71 of papillary RCC, 28 of chromophobe RCC, 1 of collecting duct carcinoma and 6 of RCC not otherwise specified, with a mean clinical followup of 7.5 years (median 6.4) were included in the study. Results: There were 115 pT1a (44.4{\%}), 95 pT1b (36.7{\%}) and 49 pT2 tumors (18.9{\%}). Disease recurrences (DR) and disease specific death occurred in 2 (1.7{\%}) and 0 cases (0{\%}) of pT1a, 7 (7.3{\%}) and 5 (5.3{\%}) of pT1b, and 16 (32.6{\%}) and 12 (24.5{\%}) of pT2. DR for pT1b was higher compared with pT1a (all histological subtypes RR 3.68), although this difference was not statistically significant (p = 0.106). If only CRCCs were analyzed, DR in the pT1b group was statistically higher compared with pT1a (RR 8.54, p = 0.047). Disease specific survival in pT1a could not be evaluated because no deaths occurred in this subgroup. DR and disease specific survival were significantly different between pT1b and pT2 tumors for all histological subtypes (RR 5.51, p = 0.001 and 5.49, p = 0.001) and for the CRCC subtype (RR 5.50, p = 0.001 and 5.18, p = 0.005, respectively). Using size as a continuous variable the logarithmic change in tumor size was a significant predictor of DR (RR 8.82, p = 0.001). All statistical analyses were adjusted for age and sex. Conclusions: Substaging RCC into pT1a and pT1b yields prognostically important information, validating the 2002 TNM modification for malignant renal epithelial malignancies. The substratification of pT1 is particularly useful in tumors with CRCC histology.",
keywords = "Carcinoma, Kidney, Neoplasm staging, Renal cell",
author = "Mohamed Salama and K. Guru and H. Stricker and E. Peterson and J. Peabody and M. Menon and Amin, {M. B.} and {De Peralta-Venturina}, M.",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.ju.0000154693.68717.12",
language = "English (US)",
volume = "173",
pages = "1492--1495",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - pT1 substaging in renal cell carcinoma

T2 - Validation of the 2002 TNM staging modification of malignant renal epithelial tumors

AU - Salama, Mohamed

AU - Guru, K.

AU - Stricker, H.

AU - Peterson, E.

AU - Peabody, J.

AU - Menon, M.

AU - Amin, M. B.

AU - De Peralta-Venturina, M.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Purpose: Tumor size has been used as one of the criteria to stratify renal cell carcinoma (RCC) into different pathological stages (pT). The recent 2002 UICC/TNM classification of malignant epithelial renal tumors is modified to substratify pT1 RCC into pT1a (less than 4.0 cm) and pT1b (greater than 4.0 but less than 7.0 cm). In this study we ascertained if this stage modification has prognostic relevance. Materials and Methods: A total of 259 consecutive radical nephrectomy specimens of organ confined RCC from 1970 to 1997 at 1 institution, including 153 of conventional RCC (CRCC), 71 of papillary RCC, 28 of chromophobe RCC, 1 of collecting duct carcinoma and 6 of RCC not otherwise specified, with a mean clinical followup of 7.5 years (median 6.4) were included in the study. Results: There were 115 pT1a (44.4%), 95 pT1b (36.7%) and 49 pT2 tumors (18.9%). Disease recurrences (DR) and disease specific death occurred in 2 (1.7%) and 0 cases (0%) of pT1a, 7 (7.3%) and 5 (5.3%) of pT1b, and 16 (32.6%) and 12 (24.5%) of pT2. DR for pT1b was higher compared with pT1a (all histological subtypes RR 3.68), although this difference was not statistically significant (p = 0.106). If only CRCCs were analyzed, DR in the pT1b group was statistically higher compared with pT1a (RR 8.54, p = 0.047). Disease specific survival in pT1a could not be evaluated because no deaths occurred in this subgroup. DR and disease specific survival were significantly different between pT1b and pT2 tumors for all histological subtypes (RR 5.51, p = 0.001 and 5.49, p = 0.001) and for the CRCC subtype (RR 5.50, p = 0.001 and 5.18, p = 0.005, respectively). Using size as a continuous variable the logarithmic change in tumor size was a significant predictor of DR (RR 8.82, p = 0.001). All statistical analyses were adjusted for age and sex. Conclusions: Substaging RCC into pT1a and pT1b yields prognostically important information, validating the 2002 TNM modification for malignant renal epithelial malignancies. The substratification of pT1 is particularly useful in tumors with CRCC histology.

AB - Purpose: Tumor size has been used as one of the criteria to stratify renal cell carcinoma (RCC) into different pathological stages (pT). The recent 2002 UICC/TNM classification of malignant epithelial renal tumors is modified to substratify pT1 RCC into pT1a (less than 4.0 cm) and pT1b (greater than 4.0 but less than 7.0 cm). In this study we ascertained if this stage modification has prognostic relevance. Materials and Methods: A total of 259 consecutive radical nephrectomy specimens of organ confined RCC from 1970 to 1997 at 1 institution, including 153 of conventional RCC (CRCC), 71 of papillary RCC, 28 of chromophobe RCC, 1 of collecting duct carcinoma and 6 of RCC not otherwise specified, with a mean clinical followup of 7.5 years (median 6.4) were included in the study. Results: There were 115 pT1a (44.4%), 95 pT1b (36.7%) and 49 pT2 tumors (18.9%). Disease recurrences (DR) and disease specific death occurred in 2 (1.7%) and 0 cases (0%) of pT1a, 7 (7.3%) and 5 (5.3%) of pT1b, and 16 (32.6%) and 12 (24.5%) of pT2. DR for pT1b was higher compared with pT1a (all histological subtypes RR 3.68), although this difference was not statistically significant (p = 0.106). If only CRCCs were analyzed, DR in the pT1b group was statistically higher compared with pT1a (RR 8.54, p = 0.047). Disease specific survival in pT1a could not be evaluated because no deaths occurred in this subgroup. DR and disease specific survival were significantly different between pT1b and pT2 tumors for all histological subtypes (RR 5.51, p = 0.001 and 5.49, p = 0.001) and for the CRCC subtype (RR 5.50, p = 0.001 and 5.18, p = 0.005, respectively). Using size as a continuous variable the logarithmic change in tumor size was a significant predictor of DR (RR 8.82, p = 0.001). All statistical analyses were adjusted for age and sex. Conclusions: Substaging RCC into pT1a and pT1b yields prognostically important information, validating the 2002 TNM modification for malignant renal epithelial malignancies. The substratification of pT1 is particularly useful in tumors with CRCC histology.

KW - Carcinoma

KW - Kidney

KW - Neoplasm staging

KW - Renal cell

UR - http://www.scopus.com/inward/record.url?scp=17144384818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144384818&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000154693.68717.12

DO - 10.1097/01.ju.0000154693.68717.12

M3 - Article

C2 - 15821466

AN - SCOPUS:17144384818

VL - 173

SP - 1492

EP - 1495

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -